Mayne Pharma Group (AU:MYX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mayne Pharma Group has announced a significant change in the securities interest of its director, Shawn Patrick O’Brien. As of December 2, 2024, O’Brien acquired an additional 301,455 Performance Rights and 35,170 RSU Performance Rights, increasing his direct holdings. This change reflects O’Brien’s growing stake in the company, potentially signaling confidence in Mayne Pharma’s future performance.
For further insights into AU:MYX stock, check out TipRanks’ Stock Analysis page.